🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma

RecruitingPhase 2Ages 18 Years - 75 YearsAllEye & ENT Hospital of Fudan University
NCT07248956 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a multi-center, randomized controlled, prospective clinical study.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Willingness to provide written informed consent; 2. Age ≥18 and ≤75 years; 3. Treatment-naïve for malignant disease; 4. Resectable stage III-IVA hypopharyngeal carcinoma with response of PR ≥ 50% after neoadjuvant therapy according to RECIST 1.1 ; 5. ECOG performance status 0-2. Exclusion Criteria: 1. Pregnancy or breastfeeding status; 2. Hypersensitivity to sintilimab, nab-paclitaxel, or their formulation components; 3. Poorly controlled cardiovascular conditions or other diseases; 4. Active or documented history of autoimmune diseases requiring systemic treatment; 5. Synchronous or metachronous malignancies; 6. Other conditions deemed ineligible for the study by investigators.
💊

What it tests

  • Finolizumab
  • Albumin-Bound Paclitaxel /nab-Paclitaxel
  • Cisplatin
  • Definitive radiotherapy
  • Surgery with postoperative radiotherapy or chemoradiotherapy.
📍

Where

7 sites
Harbin Medical University Cancer Hospital
Harbin, China
Shandong Provincial ENT Hospital
Jinan, China
Beijing Tongren Hospital, Capital Medical University
Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
Eye & ENT Hospital, Fudan University
Shanghai, China
Zhongshan Hospital of Fudan University
Shanghai, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy